NASDAQ:FTH Sensei Biotherapeutics Q1 2026 Earnings Report $28.02 +1.91 (+7.32%) Closing price 04:00 PM EasternExtended Trading$27.20 -0.82 (-2.94%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sensei Biotherapeutics EPS ResultsActual EPS-$131.45Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASensei Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASensei Biotherapeutics Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Sensei Biotherapeutics Earnings HeadlinesFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2026 | businesswire.comSensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $245,386.83 in StockJune 29, 2026 | americanbankingnews.comIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest technology bets in U.S. history. George Gilder, who has tracked technology signals for over 40 years, believes Washington just tipped its hand. He says this move points to a coming shift in computing that could leave today's machines behind - and most investors have already moved past the headline.July 8 at 1:00 AM | Eagle Publishing (Ad)Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Buys $155,937.50 in StockJune 29, 2026 | americanbankingnews.comSee More Sensei Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email. Email Address About Sensei BiotherapeuticsSensei Biotherapeutics (NASDAQ:FTH) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue. Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development. Sensei Biotherapeutics is headquartered in the United States and has focused primarily on advancing its programs through preclinical and clinical development rather than commercial sales. The company was founded to address challenges in cancer immunotherapy by engineering biologics that can be selectively activated in tumors. Sensei Biotherapeutics is led by an experienced management team and board with backgrounds in drug development and biotechnology, though leadership details can change over time.View Sensei Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Exxon Could Be the Market's Next Big Comeback StockWhy Penguin Solutions May Be the Smartest AI Infrastructure StockMeta Platforms’ Cloud Push: Growth Opportunity Versus AI ConcernsThese 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialDrone Stocks Are Down, But Defense Backlogs Tell a Different StoryGE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
